Venture Capital Investor List:

Top Pharmaceuticals Series B Investors (17)

Know someone who's actively diligencing and investing? Add them to this list.
About this list
We’ve compiled a list of the top Pharmaceuticals Venture Capital investors. The goal is to help Founders find the best investors to target and get introduced to.
Photo of Frank Torti, Partner at New Enterprise Associates
Photo of Frank Torti, Partner at New Enterprise Associates
Frank Torti
Sweet spot: $10.0M
Range: $200K - $40.0M
Investors in Health & hospital services, Investors in Health & hospital services, Investors in Pharmaceuticals, Investors in Pharmaceuticals, Investors in San Francisco Bay Area (Other Lists), Investors in Social mobile, Investors in Social mobile
Photo of Jake Nunn, Partner at New Enterprise Associates
Photo of Jake Nunn, Partner at New Enterprise Associates
Jake Nunn
Sweet spot: $10.0M
Range: $200K - $40.0M
Investors in Health & hospital services, Investors in Health & hospital services, Investors in Pharmaceuticals, Investors in Pharmaceuticals, Investors in San Francisco Bay Area (Other Lists), Investors in Social mobile, Investors in Social mobile
Photo of Paul Walker, Partner at New Enterprise Associates
Photo of Paul Walker, Partner at New Enterprise Associates
Paul Walker
Sweet spot: $10.0M
Range: $200K - $40.0M
Photo of Carol Gallagher, Partner at New Enterprise Associates
Photo of Carol Gallagher, Partner at New Enterprise Associates
Carol Gallagher
Sweet spot: $10.0M
Range: $200K - $40.0M
Photo of Justin Klein, Partner at New Enterprise Associates
Photo of Justin Klein, Partner at New Enterprise Associates
Justin Klein
Sweet spot: $10.0M
Range: $200K - $40.0M
Investors in Washington (DC)
Investors in Biotech, Investors in Biotech, Investors in Health & hospital services, Investors in Health & hospital services, Investors in Medical devices, Investors in Medical devices, Investors in Pharmaceuticals, Investors in Pharmaceuticals, Investors in Social mobile, Investors in Social mobile
AB
AB
Ali Behbahani
Sweet spot: $10.0M
Range: $200K - $40.0M
Investors in Washington (DC)
Investors in Biotech, Investors in Biotech, Investors in Health & hospital services, Investors in Health & hospital services, Investors in Health IT, Investors in Health IT, Investors in Medical devices, Investors in Medical devices, Investors in Pharmaceuticals, Investors in Pharmaceuticals
Photo of David Mott, General Partner at New Enterprise Associates
Photo of David Mott, General Partner at New Enterprise Associates
David Mott
New Enterprise Associates·General Partner
Sweet spot: $10.0M
Range: $200K - $40.0M
Investors in Washington (DC)
Investors in Biotech, Investors in Biotech, Investors in Health & hospital services, Investors in Health & hospital services, Investors in Pharmaceuticals, Investors in Pharmaceuticals
Photo of Sara Nayeem, Partner at New Enterprise Associates
Photo of Sara Nayeem, Partner at New Enterprise Associates
Sara Nayeem
Sweet spot: $10.0M
Range: $200K - $40.0M
Photo of Ed Mathers, Partner at New Enterprise Associates
Photo of Ed Mathers, Partner at New Enterprise Associates
Ed Mathers
Sweet spot: $10.0M
Range: $200K - $40.0M
Investors in Washington (DC)
Investors in Health & hospital services, Investors in Health & hospital services, Investors in Pharmaceuticals, Investors in Pharmaceuticals
Photo of Dylan  Morris, General Partner at CRV
Photo of Dylan  Morris, General Partner at CRV
Dylan Morris
CRV·General Partner
Sweet spot: $13.0M
Range: $500K - $20.0M
Investors in Boston / New England, Investors in SF Bay Area (CA)
Investors in Biotech, Investors in Medical devices, Investors in Pharmaceuticals
Get new data & insights delivered to your inbox
Venture Capital Firms investing in this space